Longitudinal Observational Study of Severe Asthma
严重哮喘的纵向观察研究
基本信息
- 批准号:9550561
- 负责人:
- 金额:$ 66.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adrenal Cortex HormonesAdverse effectsAffectAmericanApolipoprotein A-IAsthmaBiological MarkersChronicClinicalClinical DataCollectionCritical CareDataDiseaseExtrinsic asthmaGoalsHDL-triglycerideHigh Density Lipoprotein CholesterolHigh Density LipoproteinsIndividualInflammationJournalsLinkLongitudinal observational studyManuscriptsMeasuresMedicineNMR SpectroscopyNatural HistoryObstructionOutcomePathogenesisPathogenicityPathway interactionsPatientsPhenotypePhysiologicalProtocols documentationPublic HealthPublishingPulmonary Function Test/Forced Expiratory Volume 1ResistanceSerumSeverity of illnessSpecimenSteroidsTestingTimeTriglyceridesasthmaticbasecohortcost effectivedisorder controleffective therapyeosinophilnovelnovel therapeuticsparticleperiostinpersonalized managementpersonalized medicinerespiratory
项目摘要
Asthma is a common disease and a significant public health problem, affecting one in every 10 individuals, nearly 30 million people in the US alone. About 5-10% of asthmatics have severe disease that is difficult to control with standard therapies. Severe asthmatics are considered to be relatively resistant to corticosteroids, a mainstay of therapy in asthma. Furthermore, chronic corticosteroid therapy often results in side effects that adversely affect outcomes. Thus, more effective treatment options, which are safe, cost-effective and easy to administer, are needed for severe asthmatics. A better understanding of the different factors that contribute to disease severity and pathogenesis will be necessary to identify new, personalized treatment and management approaches for severe asthmatics. Our goal is to gain a better understanding of the pathogenic mechanisms that differentiate severe asthma from mild to moderate asthma. In so doing, we hope to discover novel pathways that can be targeted to achieve our primary aim of developing new therapies for severe asthmatics.
Progress achieved under this protocol is summarized as follows:
1. Serum levels of apolipoprotein A-I and large High Density Lipoprotein particles have been shown to be positively correlated with FEV1 in patients with atopic asthma. This demonstrates that circulating HDL particles are associated with less severe airflow obstruction in allergic asthma. A manuscript describing these finding has been published in the American Journal of Respiratory and Critical Care Medicine.
2. Serum levels of high-density lipoproteins have been shown to be negatively correlated with biomarkers of type 2 inflammation (e.g., blood eosinophil counts and serum periostin levels) in atopic asthmatics. In atopic asthmatics, blood eosinophils negatively correlated with serum HDL-cholesterol and total HDL particles measured by NMR spectroscopy (HDLNMR). Serum periostin levels negatively correlated with total HDLNMR. In contrast, blood eosinophil counts positively correlated with serum triglyceride levels. This study demonstrates for the first time that HDL particles were negatively correlated, whereas serum triglycerides were positively correlated, with blood eosinophils in atopic asthmatics. This finding supports the concept that serum levels of HDL and triglycerides may be linked to systemic type 2 inflammation in atopic asthma.
哮喘是一种常见疾病,也是一个重大的公共卫生问题,每10个人中就有一个患有哮喘,仅在美国就有近3000万人。大约5%-10%的哮喘患者患有严重的疾病,这些疾病很难用标准的治疗方法来控制。重症哮喘患者被认为对皮质类固醇类药物相对耐受,皮质类固醇是哮喘的主要治疗方法。此外,慢性皮质类固醇治疗经常会导致副作用,对预后产生不利影响。因此,对严重哮喘患者来说,需要更有效的治疗方案,这些方案安全、经济、易于管理。更好地了解影响疾病严重程度和发病机制的不同因素将是确定重症哮喘患者新的、个性化的治疗和管理方法所必需的。我们的目标是更好地了解区分重度哮喘和轻度至中度哮喘的发病机制。通过这样做,我们希望发现新的途径,可以有针对性地实现我们的主要目标,即为严重哮喘患者开发新的治疗方法。
在该议定书下取得的进展概述如下:
1.特应性哮喘患者血清载脂蛋白A-I和大颗粒高密度脂蛋白水平与FEV1呈正相关。这表明,在过敏性哮喘中,循环中的高密度脂蛋白颗粒与较轻的气流阻塞有关。一份描述这些发现的手稿已经发表在《美国呼吸与重症护理医学杂志》上。
2.在特应性哮喘患者中,血清高密度脂蛋白水平与2型炎症的生物标志物(如血嗜酸粒细胞计数和血清Periostin水平)呈负相关。在特应性哮喘患者中,血中嗜酸性粒细胞与血清高密度脂蛋白-胆固醇和核磁共振波谱测定的总高密度脂蛋白颗粒呈负相关。血清Periostin水平与总高密度脂蛋白核磁共振呈负相关。相比之下,血中嗜酸性粒细胞计数与血清甘油三酯水平呈正相关。这项研究首次证明,在特应性哮喘患者中,高密度脂蛋白颗粒与血中嗜酸性粒细胞呈负相关,而血清甘油三酯与其呈正相关。这一发现支持了血清高密度脂蛋白和甘油三酯水平可能与特应性哮喘的系统性2型炎症有关的概念。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stewart Levine其他文献
Stewart Levine的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stewart Levine', 18)}}的其他基金
Identification and Characterization of microRNA Genes in Asthma
哮喘中 microRNA 基因的鉴定和表征
- 批准号:
8939833 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
盐酸吡格列酮治疗严重难治性哮喘的研究
- 批准号:
8344773 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
Characterization of the Role of NUCB2 in Asthma Pathogenesis
NUCB2 在哮喘发病机制中作用的表征
- 批准号:
8558006 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
ID of Biomarkers in Exhaled Breath Condensates from Asthmatic Patients
哮喘患者呼出气体冷凝物中生物标志物的识别
- 批准号:
7734981 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
Asthma Sample Collection Protocol: Defining the Role of Apolipoprotein Pathways in Asthma
哮喘样本采集方案:定义载脂蛋白通路在哮喘中的作用
- 批准号:
10929167 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
Development of Apolipoprotein-based Therapeutics for Asthma
基于载脂蛋白的哮喘疗法的开发
- 批准号:
8149566 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
Defining Apolipoprotein-mediated Regulatory Pathways in Asthmatic Airways
定义哮喘气道中载脂蛋白介导的调节途径
- 批准号:
9550553 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
ID of Biomarkers in Exhaled Breath Condensates from Asthmatic Patients
哮喘患者呼出气体冷凝物中生物标志物的识别
- 批准号:
7969044 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
Identifying and Characterizing "Corticosteroid-unresponsive" Genes in Asthma
哮喘中“皮质类固醇无反应”基因的识别和特征分析
- 批准号:
8557924 - 财政年份:
- 资助金额:
$ 66.52万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 66.52万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 66.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 66.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 66.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 66.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 66.52万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 66.52万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 66.52万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 66.52万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 66.52万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




